Pharmaceuticals

Neurological Disorder Drugs Market Expected to Show Steady Growth, Approaching $116.27 Billion by 2030

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Neurological Disorder Drugs Market Projected To Become By 2030 Based On Its 2026 Valuation?

The neurological disorder drugs market has experienced substantial growth in recent years. This market is set to expand from $89.24 billion in 2025 to $94.49 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The historical growth witnessed in this sector can be primarily attributed to the increasing incidence of epilepsy and neurodegenerative conditions, the aging global populace, the ongoing use of symptomatic neurological medications, the broadened provision of hospital-based neurological services, and improved diagnosis rates for neurological disorders.

The neurological disorder drugs market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $116.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This expansion during the forecast period is driven by improvements in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s disease, enhanced availability of neurological care in developing markets, a growing need for tailored neurology treatments, and the wider provision of homecare and outpatient neurological therapy. Key developments expected during this period involve the increasing integration of disease-modifying neurological treatments, a heightened focus on prompt diagnosis and sustained disease management, an escalating requirement for combined drug therapies, the broader availability of oral and home-based neurological interventions, and a greater emphasis on mitigating symptoms and enhancing patient quality of life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Primary Drivers Are Shaping The Development Of The Neurological Disorder Drugs Market?

The rising occurrence of neurological diseases is anticipated to boost the expansion of the neurological disorder drugs market in the future. Neurological disorders encompass conditions affecting the brain, spinal cord, and nerves, arising from structural, biochemical, or electrical abnormalities that lead to various symptoms. This increase in neurological diseases is linked to an aging global demographic and greater exposure to environmental, metabolic, and lifestyle risk factors. Medications for neurological disorders are crucial for managing these intricate conditions, offering symptomatic relief, slowing disease progression, and enhancing patients’ long-term prognoses. As an illustration, the Australian Institute of Health and Welfare, a government body based in Australia, reported in September 2024 a projection that the number of individuals living with dementia in Australia will more than double from approximately 411,100 in 2023 to 849,300 by 2058, affecting around 315,500 men and 533,800 women. Consequently, the growing frequency of neurological illnesses is propelling the advancement of the neurological disorder drugs market.

What Segment Groups Are Identified Within The Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Advancing Progress In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are focusing on developing innovative solutions such as Ocrelizumab-based therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, helping reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), which is a twice-yearly, approximately 10-minute subcutaneous injection. This marked the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is designed to improve convenience, expand access to therapy, and support clinical workflow efficiency by offering a faster, non-intravenous method of administration.

Which Companies Hold Significant Positions In The Neurological Disorder Drugs Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Read the full neurological disorder drugs market report here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

How Does The Neurological Disorder Drugs Market Perform Across Major Global Regions?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurological Disorder Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795